|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||12.55 / 24.03|
Under proposed transaction's terms, Horizon Pharma would acquire all outstanding shares of Depomed for $29.25 each in an all-stock transaction, a 42% premium to its closing price on Monday.
U.S. stocks extend losses after reports suggest European leaders could push Greece out of the eurozone if the debt-laden nation doesn't come up with a viable reform proposal.
U.S. stock futures rise on hopes European leaders will provide short-term liquidity to Greek banks.
Like other specialty pharmaceutical makers headquartered in tax-friendly countries, Horizon is buying growth.
The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.
Trade-Ideas LLC identified Horizon Pharma (HZNP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Trade-Ideas LLC identified Horizon Pharma (HZNP) as a post-market laggard candidate
TheStreet's Jim Cramer likes Horizon Pharma for more upside and says chip companies are smart to diversify their business streams.
Why shouldn't Verizon buy Yahoo!? Cramer asks. He also likes the technical indicators for Apple and Salesforce.com.
Google buying Twitter? Verizon buying Yahoo!? Johnson & Johnson buying Bristol-Myers? Why not? Cramer asks.
Cramer is impressed by Rite Aid, even though it is expensive, and Receptos, which he says is the best early-stage biotech.
Cramer will be watching earnings from Sears, Lululemon and Cisco, among others, next week.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Trade-Ideas LLC identified Horizon Pharma (HZNP) as a new lifetime high candidate
Horizon Pharmaceuticals (HZNP) stock performance is the subject of today's Trifecta Stocks 'Chart of the Day' analysis.
Trade-Ideas LLC identified Horizon Pharma (HZNP) as a "dead cat bounce" (down big yesterday but up big today) candidate
Horizon Pharma (HZNP) reported first quarter earnings that missed expectations though revenue topped estimates.
Cramer says Horizon Pharmaceuticals is a winner but he's no fan of Oneok.
A rejuvenated stock market is still possible, Cramer says.
Horizon Pharma (HZNP) shares are climbing in after-hours trading today after the company priced its secondary public offering at $28.25 per share.
From earnings to activist investors, Cramer said investors need to focus on the good things now happening in the markets.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.